Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia
NCT05139095Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jan 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab and Rivoceranib in gestational trophoblastic neoplasia (GTN) (2 cohorts), sponsored by Peking Union Medical College Hospital. Primary endpoints: Complete Remission Rate at 1 year and Objective Response Rate at 1 year. Started Jan 2022; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
gestational trophoblastic neoplasia (GTN)
Beyond the preview
Go deeper on NCT05139095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05139095.